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Abstract
Background: Severe acute respiratory syndrome (SARS) caused a large outbreak of pneumonia
in Beijing, China, in 2003. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to
detect and quantify SARS-CoV in 934 sera and self-collected throat washes and fecal samples from
271 patients with laboratory-confirmed SARS managed at a single institution.
Results: SARS-CoV detection rates in sera were highest in the first 9 days of illness, whereas
detection was highest in throat washes 5–14 days after onset of symptoms. The highest SARS-CoV
RT-PCR rates (70.4–86.3%) and viral loads (log10 4.5–6.1) were seen in fecal samples collected 2–
4 weeks after the onset of clinical illness. Fecal samples were frequently SARS-CoV RT-PCR
positive beyond 40 days, and occasional sera still had SARS-CoV detected after 3 weeks of illness.
Conclusion: In the context of an extensive outbreak with major pressure on hospital resources,
patient self-collected samples are an alternative to nasopharyngeal aspirates for laboratory
confirmation of SARS-CoV infection.
Background
Severe acute respiratory syndrome (SARS) emerged in late
2002, with more than 8096 cases reported by April 21
2004 by the World Health Organization, mostly in China
(5327), Taiwan, Hong Kong SAR, Singapore and Canada.
There were 774 deaths and a mortality of 9.6% [1]. The
largest outbreak was in Beijing, with over 2,521 cases [2].
The SARS-associated coronavirus (SARS-CoV) was identi-
fied as the causal agent following its isolation and detec-
tion by electron microscopy and reverse transcriptase
polymerase chain reaction (RT-PCR) from a range of clin-
ical specimens. Serological evidence of infection has been
found in most patients fitting the clinical definition of
SARS [3-6]. The clinical, radiological, and laboratory find-
ings of SARS from Beijing and elsewhere have been
described previously [2,5,7-12].
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The aim of this study was to detect and quantify SARS-
CoV using RT-PCR in sera and throat washes and stools
self-collected by 271 patients with laboratory confirmed
SARS managed at a single institution. These samples were
collected during the extreme pressure of the Beijing SARS
outbreak in the context of healthcare worker concern
about the safety of collecting nsaopharyngeal aspirates
(NPAs) from ill patients.
Results
Between March 26-May 31 2003, 304 patients fitting the
case definition of probable SARS were hospitalized. Of
these, 271 were laboratory confirmed following the detec-
tion of SARS-CoV-specific IgM and/or IgG antibody by
immunofluorescence [6] and/or by the detection of SARS-
CoV RNA by RT-PCR.
The mean age of the cohort was 36 ± 16 years. There were
92 (33.9%) healthcare workers who acquired SARS,
including 51 nurses, 30 physicians, 5 logistics staff, 3
pharmacists and 2 laboratory technicians (one of whom
was believed to be infected after handling sputum and
stool samples from SARS patients in a diagnostic labora-
tory). A total of 112 people were infected following expo-
sure to SARS patients in the hospital setting, either as
healthcare workers, patients or visitors, and another 62
cases were household contacts of known SARS cases.
Common clinical features on admission included fever
(100%), subjective shortness of breath (57%), nonpro-
ductive cough (55%), malaise (52%), myalgia (38%),
headache (30%), dyspnea (21%), chills (17%), diarrhea
(11%) and sore throat (6%). The mortality rate was 9.2%
(25/271) amongst laboratory-confirmed cases.
Sera, throat washes and stool samples were tested for
SARS-CoV RNA by RT-PCR. A total of 614 sera (ranging
from 1–7 per patient) were collected 1–78 days after the
onset of illness from 271 cases. Overall, 31.3% (192/614)
of sera had detectable amounts of SARS-CoV RNA
detected, with viral loads ranging from 101-103 copies/ml
serum (Table 1). Sera collected within 9 days of disease
onset were more likely to be RT-PCR positive (54%) than
later in the disease course, although SARS-CoV RNA was
still occasionally detected in sera out to 24 days of illness.
A single throat wash was self-collected by 96 patients 1 to
35 days after the onset of disease. A total of 50 (52.1%)
had SARS-CoV RNA detected by RT-PCR (Table 2), with
viral loads ranging from 101-105 copies/ml wash fluid.
The highest detection rate was 61% in throat washes col-
lected between days 5 and 14.
Of 224 stool samples self-collected by 188 patients (1–2
samples each), 127 (56.7%) had SARS-CoV RNA detected
by RT-PCR (Table 3). Stool samples were not collected in
the first 10 days of illness, but high rates of SARS-CoV
RNA detection (44/51, 86.3%) were seen in stools col-
lected between 10 and 19 days after onset. Viral loads in
stool were as high as 1010 copies/g feces from day 10. Fecal
samples collected 40 days or more after onset of disease
contained SARS-CoV RNA in 29.8% (17/57) of samples,
with a mean load of 7000 copies/g feces. The fecal load of
SARS-CoV was at least between 2 and 3 logs higher than
in throat washes or sera at comparable time points.
Discussion
The clinical features of this cohort of 271 patients man-
aged at a single institution were similar to those reported
elsewhere [2,5,7-12], although diarrhea was present in
only 11% of patients compared to rates of 20–73%
reported in studies from Hong Kong and Canada [7-9].
Like other SARS outbreaks, many cases (41.3%) were
acquired after exposure in the hospital environment, with
healthcare workers providing 34% of cases at this institu-
tion. Of note was a case of SARS possibly acquired in a
diagnostic laboratory. There have since been a number of
cases acquired in research laboratories [1].
Detection of SARS-CoV RNA by RT-PCR is only moder-
ately useful in the early diagnosis of SARS, as the maximal
viral load and RT-PCR sensitivity occurs in the second
week of illness [9]. In addition, the sensitivity of SARS-
CoV RT-PCR on specimens collected from different sites
and at different time points in the illness varies. Testing
more than one clinical specimen increases the likelihood
of obtaining a positive RT-PCR result. In one large study,
60% of patients with clinical SARS had a positive SARS-
CoV RT-PCR in one or more clinical specimens, with the
highest detection rates in sputum (55.6%), NPAs (29.6%)
and nose/throat swabs (20%) collected within the first 5
days of illness [10]. We found that the likelihood of a pos-
itive SARS-CoV RT-PCR was similar in serum (54.3%) and
throat washes (56.6%) in the first 9 days of illness. We
found the peak of SARS-CoV detection in throat washes to
be between days 5 to 14, where 60.8% (42/69) of samples
were positive, similar to reported rates in other respiratory
specimens [9,10]. The viral loads in throat washes
decreased over time and were at levels between those in
feces and sera at similar time points.
In other studies, throat swabs were RT-PCR positive in
37.5% of probable SARS cases, reaching 50–60% on days
7–10, and consistent with earlier studies showing peaks of
virus shedding in the respiratory tract in the second week
of illness [9,11]. High viral loads were seen in NPAs in 14
patients with SARS, mainly in the second week of illness
[9]. The use of patient self-collected throat washings may
reduce risks to healthcare workers, although lower respira-
tory tract samples such as sputum, NPAs or bronchoalve-
olar lavage fluid are likely to have higher viral loads andVirology Journal 2007, 4:32 http://www.virologyj.com/content/4/1/32
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offer increased likelihood of SARS-CoV detection by RT-
PCR. We were unable to correlate viral loads in the various
clinical samples with ability to isolate virus or transmis-
sion to other people; whether viral load in the respiratory
tract correlates with 'super-shedding' events is uncertain.
Although overall SARS-CoV detection rates and viral load
in throat washes and stools were higher than in the serum,
serum SARS-CoV RT-PCR is a useful investigation early in
the illness as we found that 50% of sera had SARS-CoV
detected in the first four days of illness. One study of sera
from 8 probable SARS patients found a detectable SARS-
CoV load ranging from 2 × 103 to 1 × 104 copies/ml serum
in 50% of the samples, but not after 12 days after onset
[13]. Of interest was that occasional serum samples from
individuals remained SARS-CoV RT-PCR positive (with
moderate viral loads) over three weeks after onset of ill-
ness, a feature noted in another study [14].
High rates of SARS-CoV RT-PCR detection (as high as
86.3% between days 10–19) and high viral loads were
found in fecal samples in the second to fourth weeks of
disease. Rates of SARS-CoV detection in fecal samples
began to decrease after one month, although many stools
were still SARS-CoV RNA positive 40 days or more after
the onset of the clinical illness. The SARS-CoV load in
fecal samples collected after 40 days were higher than the
peak load seen in sera collected early in disease, and com-
parable to the viral load in throat washes in the second
week of illness. Both lower (27% in fecal samples col-
lected 11–20 days after onset) and similar high detection
rates (over 80% in stools collected 11–16 days after onset)
have been reported elsewhere, as have fecal samples posi-
tive 40 days or more after onset [10,14]. Despite the high
SARS-CoV load in feces, diarrhea was not a prominent
clinical feature in this cohort. Long-term fecal viral shed-
ding may be an additional source of community spread of
SARS, although the infectivity of feces may be better
assessed with virus isolation.
Direct comparisons of the sensitivity and specificity of RT-
PCR for the detection of SARS-CoV are hampered by the
use of different types of clinical specimens, RNA extrac-
tion procedures and different RT-PCR techniques. The
first published interlaboratory comparison showed sensi-
tivities of 61% and 68% for 72 NPAs, 65% and 72% for
54 throat swabs, 50% and 54% for 78 urine samples and
58% and 63% for 19 stool specimens, with an overall spe-
cificity of 100% [15]. To date, no significant differences in
the sensitivity and specificity of various commercial and
in-house RT-PCR or other molecular assays have been
reported [16-18].
Conclusion
SARS-CoV infection results in a severe respiratory disease.
It causes significant nosocomial infection and requires
aggressive infection control practices rarely used for other
causes of atypical pneumonia. Laboratory confirmation of
SARS is crucial in the management of patients presenting
with pneumonia, particularly as the clinical features of
SARS make it difficult to distinguish from other causes of
atypical pneumonia. Molecular methods for SARS diag-
nosis are useful, although their value is affected by the
observation that maximal viral shedding occurs after the
first week of illness rather than at the initial clinical pres-
entation. The SARS outbreak was characterized by high
Table 1: Detection and quantitation of SARS-CoV RNA by RT-PCR in sera.
Days after onset Samples Positive (number, %) Viral load (log10 copies/ml ± SD)
1–4 76 38 (50) 2.74 ± 0.88
5–9 154 87 (56.5) 2.78 ± 1.04
10–14 129 39 (30.2) 2.58 ± 1.02
15–19 88 24 (27.3) 2.27 ± 0.85
20–24 24 4 (16.7) 2.11 ± 1.04
≥25 143 0 -
Total 614 192 (31.3) 2.65 ± 0.99
Table 2: Detection and quantitation of SARS-CoV RNA by RT-PCR in throat washes.
Days after onset Samples Positive (number, %) Viral load (log10 copies/ml ± SD)
1–4 8 3 (37.5) 4.73 ± 0.45
5–9 45 27 (60) 3.59 ± 1.36
10–14 24 15 (62.5) 3.33 ± 1.37
15–19 11 5 (45.5) 1.88 ± 1.00
20–24 4 0 -
≥25 4 0 -
Total 96 50 (52.1) 3.45 ± 1.39Virology Journal 2007, 4:32 http://www.virologyj.com/content/4/1/32
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infection rates in healthcare workers; patient self-collected
specimens such as throat washes or feces, or serum may
pose less risk to healthcare workers, particularly in the
context of concerns about nosocomial acquisition.
Although NPAs and other lower respiratory tract samples
are the sample of choice for suspected respiratory viral
infections, patient self-collected specimens are suitable for
RT-PCR. Thus they offer diagnostic value, especially in
SARS where the peak of viral shedding is after the first
week of illness, and this sampling approach may reduce
the safety issues of healthcare workers collecting NPAs.
Patient self-collected specimens may be less appropriate
for common seasonal respiratory virus infections such as
influenza, where viral shedding is maximal at clinical
presentation and virus is rarely detected outside the respi-
ratory tract. Accurate and rapid laboratory diagnosis will
become even more important as SARS becomes less com-
mon, or in the event of new outbreaks of SARS, especially
if influenza or other seasonal respiratory viruses are co-cir-
culating.
Methods
This study was conducted during the first three months
(March-May 2003) of the SARS outbreak in Beijing,
China, where Ditan Hospital was designated as a 'SARS
hospital', meaning that suspected SARS patients were
transferred and managed at this institution. The study was
approved by the Ethics Committee of the Beijing Ditan
Hospital. The clinical case definition of probable SARS
included a fever of ≥38°C, cough or shortness of breath,
new pulmonary infiltrates on chest radiography, and close
contact with a suspect or probable SARS case. Day 1 was
defined as the day of fever onset.
Sera, throat washes and feces were collected from hospi-
talised patients for testing with a quantitative SARS-CoV
RT-PCR. As the early phase of the outbreak in Beijing had
involved many healthcare workers [2], patient self-col-
lected throat washes and fecal samples were used to min-
imize further nosocomial transmission. For throat
washes, patients were given 10 ml of sterile 0.9% NaCl,
asked to gargle for 30 seconds then spit the fluid into a 20
ml sterile plastic screw-topped plastic container. Patients
were also asked to collect approximately 1 cm3 feces and
place it into a 20 ml sterile screw-topped plastic container.
Five ml of the throat wash was centrifuged at 10,000 g for
10 minutes, then the supernatant further centrifuged at
20,000 g for 1 hour. Ten ml of 0.01 M phosphate buffered
saline (pH 7.2) was used to dilute the fecal sample, then
5 ml was centrifuged at 10,000 g for 10 minutes. The
supernatant was further centrifuged at 20,000 g for 1
hour. RNA was extracted from the remaining 100–300 μl
of the throat wash and fecal pellets using Trizol (Invitro-
gen, Beijing, PR China). 700 μl of sera were centrifuged at
20,000 g for 1 hour, the supernatant removed and RNA
extracted from the remaining 100–300 μl pellet using Tri-
zol.
SARS-CoV RNA was detected in throat washes, stool and
blood using a fluorescence quantitative RT-PCR assay
(ShenZhen PJ Biotech Company, Shenzhen, Guangdong
Province, PR China), according to the manufacturer's
instructions and performed on a BioRad iCycler thermal
cycler (Bio-Rad Laboratories, Beijing, PR China). The
SARS-CoV pol region primers used were P1 sense
5'GTTCTTGCTCGCAAACATAACACTT3' (position
15279–15303 in SARS-CoV Urbani strain, Genbank
accession number AY278741), P2 antisense
5'AACAGCTTGACAAATGTTAAAGACA3' (15446–15470)
and probe 5'TGTGTGGCGGCTCACTATAT3' (15373–
15392). Internal controls were used in all runs, and no
evidence of PCR inhibition in clinical samples was
detected. Testing for other respiratory viruses was not car-
ried out in this cohort of patients as they fitted the SARS
clinical case definition during the outbreak. The PCR
assay was negative when performed on RNA or DNA
extracted from influenza A and B, rhinovirus, respiratory
syncytial virus and adenovirus isolates, and on plasma
collected from otherwise healthy hepatitis C and B
infected individuals (data not shown).
Manipulations were carried out in a BSL2 facility with
BSL3 practices. SARS-CoV isolation was not attempted on
clinical samples during the outbreak due to safety con-
cerns and time constraints.
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